Demetrios Kydonieus

Mr. Kydonieus is a senior pharmaceutical executive with proven success leading small, medium, and large Biopharma companies in executing their corporate strategies, resulting in significant growth and shareholder value. Today, heis leading R-Pharm US, a differentiated specialty BioPharma company focused on Oncology and Immunology. R-Pharm US has marketed products in Oncology and assets in development for oncology and immunology.

In 2014, Mr. Kydonieus partnered with Mark Pavao to create a differentiated specialty BioPharma company. The opportunity to work with Russia's premier pharmaceutical company, R-Pharm JSC, presented a unique opportunity to accelerate the growth and importance of the BioPharma start-up (R-PHARM US). Prior to R-Pharm US, he was the Vice President, Strategy, Alliances and Transactions (SAT) at Bristol Myers Squibb (BMS) where he was instrumental in helping BMS implement the BioPharma transformation and execute the String of Pearls strategy.

Mr. Kydonieus began working at BMS in 1998 as Director, Worldwide Regulatory Affairs in the Health Care Group. After leaving the Health Care Group, he joined the Corporate Strategy and Issues Management Group as Director, Business Risk Management, where he identified and helped manage the largest risks to the BMS strategy. He later moved with his family to Boston to be General Counsel for BMS Medical Imaging, where he was a member of the business unit's Executive Team and helped lead the divestiture of the business to private equity.

Mr. Kydonieus earned his Juris Doctor degree from Quinnipiac University School of Law and his Masters of Business Administration from Duke University, Fuqua School of Business.